Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol versus salmeterol + fluticasone in moderate COPD
2011-003732-31Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Indacaterol arm with Salmeterol + fluticasone propionate arm (2 arms). Primary endpoint: Trough FEV1 at 12 weeks. Started Dec 2011; status: completed.
02
Drugs
indacaterolsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-003732-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003732-31.